🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib, Trajenta 5 mg film-coated tablets

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  2. Avastin 25 mg/ml concentrate for solution for infusion., Vectibix 20 mg/ml concentrate for solution for infusion, Folinato Cálcico Hikma, 10 mg/ml solución inyectable y para perfusión EFG, Oxaliplatino Kabi 5 mg/ml concentrado para solución para perfusión EFG, Erbitux 5 mg/mL solution for infusion, Irinotecan Hydrochloride Trihydrate Fair-Med Healthcare 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

  3. Axatilimab (INCA034176)

    Incyte

    Chronic Graft-Versus-Host Disease

    phase 2 small molecule active

    1 trial

  4. Axatilimab (INCA034176), PREDNISONE, METHYLPREDNISOLONE, Jakavi 5 mg tablets

    Incyte

    chronic graft-versus-host disease

    phase 2 small molecule active

    1 trial

  5. Azacitidine 150mg tablet, Azacitidine 200mg tablet: film- coated tablet, azacitidine, PEMBROLIZUMAB, azacitidine

    Celgene Europe Limited

    Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. B013

    BRIGHT MINDS BIOSCIENCES INC.

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  7. B10 L-BPA Injection

    Heron Therapeutics

    Meningioma

    phase 2 small molecule completed

    1 trial

  8. B10 L-BPA Injection

    Heron Therapeutics

    Malignant Brain Tumors

    phase 2 small molecule active

    1 trial

  9. BARICITINIB

    Pari Pharma GmbH

    Juvenile Dermatomyositis

    phase 2 small molecule active

    1 trial

  10. BAY 1021189

    Bayer AG

    Chronic heart failure with reduced ejection fraction

    phase 2 small molecule active

    1 trial

  11. BAY 1841788, DEGARELIX , LEUPRORELIN , TRIPTORELIN , GOSERELIN , TRIPTORELIN PAMOATE

    Ningbo Cancer Hospital

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  12. BAY 2599023

    Bayer AG

    Hemophilia A

    phase 2 small molecule active

    1 trial

  13. BAY 3283142, BAY 3283142 PLACEBO, BAY 3283142, BAY 3283142

    Bayer AG

    Chronic kidney disease

    phase 2 small molecule active

    1 trial

  14. BAY 3713372 Bayer, BAY 3713372 Bayer, -, -, -, -

    Bayer AG

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  15. BAY 73-4506, AVELUMAB

    The George Institute

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  16. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  17. BAY1002670

    Bayer HealthCare AG

    Leiomyoma

    phase 2 small molecule completed

    1 trial

  18. BB-301: Dose escalation phase 1b cohort 1

    Benitec Biopharma

    Oculopharyngeal Muscular Dystrophy

    phase 2 gene therapy active

    1 trial

  19. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  20. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb Australia Pty Ltd

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  21. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  22. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  23. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  24. BCT197

    Mereo BioPharma Group plc

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources